Sotorasib in NSCLC: ' Historic Milestone ' Reached Sotorasib in NSCLC: ' Historic Milestone ' Reached

The KRAS inhibitor sotorasib provides durable clinical benefit in heavily pretreated patients with non –small cell lung cancer (NSCLC) harboring KRAS p.G12C mutations, results of a phase 2 trial suggest.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news